非酒精性脂肪性肝炎新药研发的一些关键因素  

Key factors in the research and development of new drugs for nonalcoholic steatohepatitis

作　　者：郭朝阳[1] 芮法娟 李婕[1] GUO Zhaoyang;RUI Fajuan;LI Jie(Department of Infectious Diseases, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, China)

机构地区：[1]山东大学附属山东省立医院感染性疾病科,济南250021

出　　处：《临床肝胆病杂志》2021年第6期1254-1258,共5页Journal of Clinical Hepatology

基　　金：国家自然科学基金(81970545);山东省自然科学基金重点项目(ZR2020KH006);济南市科技发展计划项目(202019079)。

摘　　要：非酒精性脂肪性肝病(NAFLD)已成为我国第一大慢性肝病,以及欧美发达国家肝移植的主要病因。在NAFLD的各种表型中,非酒精性脂肪性肝炎(NASH)极有可能发展为包括肝硬化、肝癌在内的终末期肝病,导致肝脏相关的死亡率增加。但目前尚无针对NASH的治疗药物,许多新药正在开展临床试验中。NASH新药的研发,需要依据抗代谢、抗炎以及抗纤维化作用方式来选择合适的目标人群和治疗终点。总结和论述了目前NASH新药研发中的一些关键因素。Nonalcoholic fatty liver disease(NAFLD)has become the most important chronic liver disease in China and a major cause of liver transplantation in developed countries in Europe and America.Among the various phenotypes of NAFLD,nonalcoholic steatohepatitis(NASH)is highly likely to progress to end-stage liver disease including liver cirrhosis and liver cancer,resulting in an increase in liver-related mortality.However,there are still no therapeutic drugs for NASH at present,and many new drugs are under development in ongoing clinical trials.The research and development of new drugs for NASH require the selection of an appropriate target population and treatment outcomes depending on anti-metabolic,anti-inflammatory or anti-fibrotic effect.This article summarizes and reviews several key factors in the research and development of new drugs for NASH.

关 键 词：非酒精性脂肪性肝病 药物发现 模型 生物学 

分 类 号：R575.5[医药卫生—消化系统]